Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma

Annals of Oncology

Volumn 19, Issue 10, 2008, Pages 1770-1773

  Elstrom, R L ^a   Leonard, J P ^a   Coleman, M ^a   Brown, R K J ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Lymphoma; PET CT; Staging

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INCIDENTAL FINDING; INTERMETHOD COMPARISON; LYMPHOMA; MAJOR CLINICAL STUDY; OCCULT CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; SPLEEN DISEASE; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 53049088385     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn282     Document Type: Article

References (11)

1. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110: 3507-3516.
2. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
3. Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.
4. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
5. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284.
6. Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 2004; 232: 823-829.
7. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006; 47: 1643-1648.
8. Raanani P, Shasha Y, Perry C et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2006; 17: 117-122.
9. Gollub MJ, Hong R, Sarasohn DM, Akhurst T. Limitations of CT during PET/ CT. J Nucl Med 2007; 48: 1583-1591.
10. Mawlawi O, Erasmus JJ, Munden RF et al. Quantifying the effect of IV contrast media on integrated PET/CT: Clinical evaluation. AJR Am J Roentgenol 2006; 186: 308-319.
11. Berthelsen AK, Holm S, Loft A et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005; 32: 1167-1175.